Renaissance Technologies (RenTech)'s MLTX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 276,772 shares of MoonLake Immunotherapeutics (MLTX) worth $5.16 M, representing 0.01% of the portfolio. First purchased in 2022-Q4, this short-term holding has been held for 7 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in MLTX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 142,300 shares. Largest reduction occurred in Q4 2023, reducing 13,396 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s MoonLake Immunotherapeutics (MLTX) Holding Value Over Time
Track share changes against reported price movement
Quarterly MoonLake Immunotherapeutics (MLTX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +142,300 | Add 105.82% | 276,772 | $18.64 |
| Q4 2025 | +134,472 | New Buy | 134,472 | $13.18 |
| Q4 2023 | -13,396 | Sold Out | 0 | $0.00 |
| Q3 2023 | -2,104 | Reduce 13.57% | 13,396 | $57.03 |
| Q2 2023 | -7,200 | Reduce 31.72% | 15,500 | $0.05 |
| Q1 2023 | +11,091 | Add 95.54% | 22,700 | $0.02 |
| Q4 2022 | +11,609 | New Buy | 11,609 | $0.01 |
Renaissance Technologies (RenTech)'s MoonLake Immunotherapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased MoonLake Immunotherapeutics (MLTX) in Q4 2022, acquiring 11,609 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held MoonLake Immunotherapeutics (MLTX) for 7 quarters since Q4 2022.
Renaissance Technologies (RenTech)'s largest addition to MoonLake Immunotherapeutics (MLTX) was in Q1 2026, adding 276,772 shares worth $5.16 M.
According to the latest 13F filing for Q1 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 276,772 shares of MoonLake Immunotherapeutics (MLTX), valued at approximately $5.16 M.
As of the Q1 2026 filing, MoonLake Immunotherapeutics (MLTX) represents approximately 0.01% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in MoonLake Immunotherapeutics (MLTX) was 276,772 shares, as reported at the end of Q1 2026.